摘要
目的:观察曲美他嗪与氟伐他汀联用对急性冠状动脉综合征患者血清高敏C反应蛋白和血脂水平的影响,探讨他汀类药物与曲美他嗪在ACS治疗中的作用。方法:选择收治的ACS患者100例,采用随机、单盲、对照方法将ACS患者分对照组(n=48,每天口服安慰剂)和曲美他嗪与氟伐他汀治疗组(n=52,氟伐他汀40mg/日,曲美他嗪60mg/日,发病48小时内开始服用),两组其他治疗相同;观察4周,于治疗后分别检测患者血清hs-CRP及血脂的浓度。hs-CRP浓度采用酶联免疫吸附法测定,血脂采用酶法。结果:治疗4周后,曲美他嗪与氟伐他汀患者血清hs-CRP和总胆固醇(TC)、甘油三酯(TG)及低密度脂蛋白胆固醇(LDL-C)浓度显著降低(P均<0.01),而对照组治疗前后差异无显著性(均为P>0.05)。结论:显示曲美他嗪与氟伐他汀联用ACS患者可明显降低hs-CRP水平,改善血脂。
Goal observation tune US he qin cuts down his sandbank with the atropic to unite with to acute coronary artery syndrome（ACS）patient blood serum Gao Min C response protein（hsCRP）and the blood fats level influence,discusses his sandbank class medicine and tune US he qin in ACS in the treatment function method choice in hospital ACS patient 100 examples,uses,Shan Mang,the comparison method to divide stochastically the ACS patient the control group（n=48,takes orally placebo every day）and tune US he qin cuts down his sandbank treatment group with the atropic（n=52,atropic cuts down his sandbank 40mg/d,bends US he qin 60mg/d,is taken bad in 48 h to start to take）,two groups of other treatments are the same;Observes for 4 weeks,after treatment examines patient blood serum hsCRP and the blood fats density separately.the hsCRP density uses the enzyme to unite the immunity adsorption law determination,the blood fats uses the enzyme law.The result treats 4 weeks later,bends US he qin to cut down his sandbank patient blood serum hsCRP and total cholesterol（TC）,triglyceride（TG）and the low density lipoprotein cholesterol with the atropic（LDLC）the density obviously reduces（P〈0.01）,but around the control group treats the difference not to have the significance（is P〉005）.The result showed that tune US he qin cuts down his sandbank with the atropic to unite with the ACS patient may lower the hsCRP level obviously,the improvement blood fats.
